Jun. 12 at 5:03 PM
Intelligent Bio Solutions (Nasdaq: INBS) announced an update on its growing footprint in the U.S. Forensic Use Only Market through its strategic partnership with SMARTOX, a Texas-based leader in drug and alcohol screening services.
Intelligent Bio Solutions Inc. (NASDAQ:
$INBS) is a B2i Digital Featured Company. View its comprehensive profile at https://b2idigital.com/intelligent-bio-solutions.
Highlights from today’s announcement include:
- SMARTOX has deployed over 50 Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more than 1,500 tests in 2024 alone.
- The technology is reducing reliance on invasive methods, such as urine or saliva collection while delivering rapid and reliable results directly linked to the individual being tested.
- INBS continues to actively pursue FDA clearance for its opiate test system for codeine, aiming to enable expansion into broader U.S. markets in 2025.
- SMARTOX supports clients across various settings, including correctional facilities, drug courts, rehabilitation centers, and other forensic environments throughout the United States and international markets.
Doug Heath, Vice President of Global Sales at INBS, stated, “We have partnered with SMARTOX to expand access to our fingerprint drug screening system across forensic settings such as criminal justice. SMARTOX’s commitment to innovation aligns with our mission to transform drug testing through intelligent, non-invasive technologies.”
Read the full release: https://investors.ibs.inc/news/news-details/2025/Intelligent-Bio-Solutions-Expands-U-[…]rance-for-Breakthrough-Fingerprint-Drug-Testing/default.aspx
Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is advancing hygienic, rapid, and cost-effective fingerprint sweat testing worldwide. The company’s non-invasive, patented technology enables drug screening in under ten minutes, offering advantages over traditional testing methods. INBS serves the workplace safety, law enforcement, drug treatment, and forensics sectors, with a growing global footprint of over 450 accounts across 24 countries.
Its experienced global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli, and Peter Passaris.
For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at
[email protected], KCSA Strategic Communications.
#IntelligentBioSolutions #INBS #B2iDigital #DrugScreening #WorkplaceSafety
